2Lee AF, Mac Fadyen R J, Struthers AD. Neurohormonal reactivation in heart failure patients on chronic ACE inhibitor therapy : a longitudinal study[ J]. Eur J Heart Fail, 1999,1 (4) :401-406.
3Rouleau JL, Packer M, Moye L, et al. Prognostic value of neurohumoral activation in Patients with an acute myocardial infarction: effect of captopril [J] .J Am Coll Cardiol, 1994,24(3) :583-591.
4Bauer JH,Reams GP.The angiotensin Ⅱ type Ⅰ receptor antagonists, A new class of anti-hypertensive drugs[ J]. Arch Intern Med, 1995,155 (13): 1361-1368.
5Regitz ZV, Neuss M, Warnecke C, et al. Angiotensin receptors organ and subtype specific regulation in cardiovascular diseases by modulation of the rennin-angiotensin system,studies of therate modeland in human myocardium[ J]. Z Cardiol, 1995,84 [ Suppl 4 ]: 61-63.
6Goodfriend TL,Elliott ME,Catt KJ.Drug therapy:angiotensin receptors and their antagonists[J] .N Engl J Med, 1996,334(25):1649-1654.
7Wilke A, Funck R, Rupp H, et al. Effect of the rennin-angiotensin-aldosterone system on the cardiac interstitium in heart failure [J]. Basic Res Cardiol,1996,91[Suppl 2] :79-84.
8Asmar R, Makonna O, Brisac AM, et al. Comparison between the ef fects of angiotensin-converting-enzyme inhibitors and angiotensin Ⅱ antagonists[ J]. Therapie, 1998,53(3) :253-270.
9Weber KT, Villarreal D. Aldosterone and antialosteroe therapy in congestive heart failure[ J]. Am J Cardlol, 1993,71 [ Suppl ]: s3-s1 1.
10Eichhorn E J, Bristow MR. Medical therapy can improve the biological properties of the chronically failing heart[J]. Circulation, 1996,94(9): 2285-2296.
